Addressing Key Challenges in Viral Hepatitis Management

By following simplified management guidelines, primary care professionals can easily diagnose and treat HCV, which can only help our patients engage in HCV treatment.

Stacey Trooskin, MD, PhD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 6, 2021 Expired: August 5, 2022

With only a minority of US patients with chronic HBV infection being tested for HDV coinfection, the most critical milestone for identifying patients with HDV is increasing HDV awareness among healthcare workers.

Takeshi Saito, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 20, 2021 Expired: August 19, 2022

Simplified approaches to HCV treatment help treat and cure HCV in more of our patients and take us closer to the goal of HCV elimination.

Stacey Trooskin, MD, PhD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 31, 2021 Expired: August 30, 2022

Approval of bulevirtide in Europe and promising clinical trial results with lonafarnib signal that new management options for patients with hepatitis delta are on the horizon.

Takeshi Saito, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 28, 2021 Expired: September 27, 2022

Community engagement and collaboration with healthcare systems can boost uptake of HBV screening and care.

Julie Dang, PhD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 18, 2021 Expired: November 17, 2022

My take on how social determinants of health influence liver disease prevalence, outcomes, and treatment access in the United States; how the COVID-19 pandemic has exacerbated these disparities; and what interventions are needed from healthcare professionals and institutions to address these health inequities.

Ani Kardashian, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 23, 2021 Expired: November 22, 2022

How I overcame barriers to receiving specialist treatment and care following my diagnosis with chronic HBV infection.

Jacki Chen, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 9, 2021 Expired: December 8, 2022

A 3-pronged approach to HCV elimination in MSM patients with HIV and HCV: test, treat, and counsel.

Dominique Laurent Braun, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 10, 2022 Expired: January 9, 2023

New legislation requires Californian primary care professionals to offer voluntary screening for hepatitis B and C to all patients.

Samuel So, MBBS, FACS Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: March 8, 2022 Expired: March 7, 2023

The long journey from HCV screening to treatment initiation presents a substantial barrier that results in considerable loss of continuity along the HCV care cascade and impedes global HCV elimination efforts. Read this commentary to hear my thoughts on key strategies that can dramatically reduce the burden of this process and how Australia is embarking on a mission to initiate HCV treatment on the same day that patients are screened.

Jason Grebely, BSc, PhD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: March 2, 2022 Expired: March 1, 2023

Here’s what I include and what I leave out (and why) when conducting a thorough clinical workup for patients with newly diagnosed HBV infection.

Norah Terrault, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: March 4, 2022 Expired: March 3, 2023

Many addiction medicine sites have successfully integrated HCV services. Here’s how some have done it and why it is so important.

Oluwaseun Falade-Nwulia, MBBS, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: March 30, 2022 Expired: March 29, 2023

Here's my advice for healthcare professionals who provide care for patients with HCV infection.

Shelley Rossell Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: March 24, 2022 Expired: March 23, 2023

Vertical transmission is responsible for the majority of all chronic HBV infections worldwide, so its prevention is essential both to protect the health of the newborn and to reduce the burden of chronic HBV infection. Here are my thoughts on the important preventive roles of maternal antiviral therapy and newborn prophylaxis.

Maria Buti, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 13, 2022 Expired: April 12, 2023

Here are my thoughts on the interplay between HBV infection and pregnancy, including the effects of pregnancy on the natural history of HBV infection, the effects of HBV infection on pregnancy outcomes, and what this interplay means for care decisions.

Maria Buti, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 18, 2022 Expired: April 17, 2023

I have learned a lot through my experiences with HBV/HDV coinfection. Read this commentary to hear my perspective on what healthcare professionals could do to help improve care for people with or at risk for HBV/HDV coinfection.

Joaquín (Patient) Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 29, 2022 Expired: June 28, 2023

Current HBV treatment paradigms are being challenged, particularly when it comes to avoiding treatment for patients who fall into the so-called gray zone. Here’s my take on the risk vs benefit assessment for HBV treatment in this setting.

Carla Coffin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 21, 2022 Expired: June 20, 2023

Not being screened despite careful adherence to annual checkups and living a healthy lifestyle nearly cost me my life. Read my story to understand why every adult should be screened for HCV infection—without exception.

Sherry Tierney Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 17, 2022 Expired: May 16, 2023

In episode 1 of this ongoing series, listen to a conversation between Stacey Trooskin, MD, PhD, MPH, and patient advocate Brother Dan Palmer on approaches to improve access to HCV therapy and remove barriers to care.

Stacey Trooskin, MD, PhD, MPH Released: October 19, 2021

In episode 2 of this series, tune in to a conversation between Robert G. Gish, MD, and patient advocate Jacki Chen, PhD, about the potential benefits of simplifying our approach to treating patients with chronic hepatitis B.

Jacki Chen, PhD Robert G. Gish, MD Released: February 24, 2022

Episode 4 of this series features a conversation between a patient, Jason, and Paul Y. Kwo, MD, who discuss the particular challenges that can affect people with chronic hepatitis B seeking care in rural settings.

Paul Y. Kwo, MD Released: March 25, 2022

Episode 3 of this series features a conversation between patient Melody Cheng and Anna Cristina L. dela Cruz, MD, who discuss Melody’s decision to start HBV antiviral therapy during pregnancy.

Anna Christina L. dela Cruz, MD Released: March 7, 2022

In this podcast, learn from expert faculty as they discuss key lessons from their own micro-elimination program designed to prevent HCV transmission among HIV-positive men who have sex with men.

Dominique Laurent Braun, MD Released: April 27, 2022

In this podcast, CCO’s expert faculty discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV.

Heiner Wedemeyer, MD Released: March 30, 2022

This episode features a conversation between a patient, Alicia, and Oluwaseun Falade-Nwulia, MBBS, MPH, who discuss how stigma in the medical system toward marginalized populations, including people who inject drugs or who have a history of injection drug use, prevents access to HCV care.

Oluwaseun Falade-Nwulia, MBBS, MPH Released: April 20, 2022

This episode features a conversation between a patient, Shelley Rossell, and Norah Terrault, MD, MPH, who discuss the importance of universal HCV screening, the ease and benefits of DAA therapy, and how patients can be effective self-advocates for, during, and after treatment

Norah Terrault, MD, MPH Released: May 3, 2022

In this podcast, CCO’s expert faculty discusses how to identify which patients with chronic HBV infection may not need immediate HBV treatment and the critical need to continue monitoring such patients even in the absence of ongoing therapy.

Pietro Lampertico, MD, PhD Released: May 26, 2022

In this podcast, an expert discusses the various definitions/types of HBV cure and different investigational approaches under evaluation for their potential to achieve cure.

Carla Coffin, MD Released: June 30, 2022